dermatology

A new year, new era in dermatology, new magazineThe word of the moment is "new!" We have a new year, a new president, we are looking at the possibility of another new organizational structure in medicine, and we are working on a new look here at Dermatology Times.
Protocol for injecting fillers gives more predictable resultsPartitioning the face into different units and injecting filler in specific locations is a method to attaining a rejuvenated face that looks relaxed and natural.
New neurotoxin on the block starts phase 3 trialsThe injectable neurotoxin drug candidate daxibotulinumtoxinA for injection (RT002, Revance Therapeutics) started phase 3 SAKURA trials in December 2016
A checklist to practice what you preach
A checklist to practice what you preachIt’s a lot simpler to help your patients if you can fully stand behind what you’re suggesting. Can you add any of these simple tips to your to-do list this week?
RF microneedling applicationsOne dermatologists describes her success with radiofreqency microneedling to treat acne and acne scarring.
New era looming MCC treatmentImmune checkpoint inhibitors are providing rapid and durable responses for patients with metastatic Merkel cell carcinoma.
FDA approves corticosteroid-sparing topical option for eczemaThe FDA announced it has approved Eucrisa (Anacor Pharmaceuticals, crisaborole) ointment to treat mild to moderate eczema in patients two-years-of-age and older.
January Clinical Considerations for NPs, PAsThis month, we take a look at when to use biologics, advances in pediatric Atopic Dermatitis (AD), and how Trump’s presidency might impact dermatology.
Burn depth difficult to determine with the naked eyeVisual assessment of a burn injury is insufficient to judge the depth of a burn; hypertrophic scars left by burn injuries are increasingly being treated with lasers with impressive results.
Rosacea treatmentsNewer topical agents for rosacea including ivermectin and brimonidine are effective, and soon could be joined by oxymetazoline cream, experts say. Initial results from phase 2 trials of minocycline foam in rosacea could be available by year's end.